Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric daptomycin versus standard of care for complicated skin and skin structure infections
2015-002778-19Phase 4
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- Jun 2015
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of daptomycin in Complicated skin and skin structure infection (cSSSI) (2 arms), sponsored by Cubist Pharmaceuticals, Inc. Primary endpoint: Evaluation of safety.
02
Drugs
daptomycin
03
Conditions
Complicated skin and skin structure infection (cSSSI)
Beyond the preview
Go deeper on 2015-002778-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002778-19.